08/18/2026

Recent Oncology Related FDA Approvals and Expanded Indications

FDA Approves Bristol Myers Squibb's first CELMoD therapy ZENBEXUS™, in combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for patients with Multiple Myeloma

FDA approves Merck's KEYTRUDA or KEYTRUDA QLEX, in combination with WELIREG, for the adjuvant treatment of adult patients with renal cell carcinoma

FDA approves Sanofi’s subcutaneous Sarclisa Escena anticancer treatment administered via on-body injector

FDA approves Lilly's selpercatinib (Retevmo) for locally advanced or metastatic RET fusion-positive solid tumors

FDA approves Celcuity's Revtorpyk™ (gedatolisib) for treatment of HR+/HER2-, PIK3CA Wild-Type locally advanced or metastatic breast cancer

 

More Info